Genmab AS (LTS:0MGB) Short-Term Capital Lease Obligation : kr97 Mil (As of Mar. 2025)

View and export this data going back to 2010. Start your Free Trial

What is Genmab AS Short-Term Capital Lease Obligation?

Genmab AS's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr97 Mil.

Genmab AS's quarterly Short-Term Capital Lease Obligation declined from Sep. 2024 (kr92 Mil) to Dec. 2024 (kr91 Mil) but then increased from Dec. 2024 (kr91 Mil) to Mar. 2025 (kr97 Mil).

Genmab AS's annual Short-Term Capital Lease Obligation increased from Dec. 2022 (kr75 Mil) to Dec. 2023 (kr91 Mil) and increased from Dec. 2023 (kr91 Mil) to Dec. 2024 (kr91 Mil).

Genmab AS Short-Term Capital Lease Obligation Historical Data

The historical data trend for Genmab AS's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Short-Term Capital Lease Obligation Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

42.45

62.12

74.80

91.33

91.42

Genmab AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															91.29	93.56	91.57	91.42	96.59

Genmab AS Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Genmab AS Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Genmab AS's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (LTS:0MGB) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMAB:Mexico GMABc:UK GMAB:Denmark GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines